If your goal is weight management rather than diabetes treatment, Wegovy or Mounjaro are the appropriate routes to explore
The Semaglutide cohort compared to the non-GLP-1RA anti-obesity medications cohort was older, had a lower prevalence of adverse socioeconomic determinants of health, mental disorders, and substance use disorders, and a higher prevalence of morbid obesity, T2D and obesity-associated comorbidities
The GLP-1 receptor pathway involves GLP-1 binding to its receptor (GLP-1R), which activates G-proteins, leading to increased cyclic adenosine monophosphate (cAMP) levels and subsequent activation of protein kinase A (PKA)
More drugs are in development, more indications are coming, and more consumers will enter the ecosystem
Some prescribing professionals have noted that when prescribing GLP1-RA for individuals with diabetes and MCAS, that the individuals also experienced improvements in inflammatory symptoms connected to MCAS